UNSPSC 51122700: Combination cardiovascular agents

This classification denotes combination drugs that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume, and thereby improve cardiovascular function, hence the term CARDIOVASCULAR AGENTS. Typical combination cardiovascular agent constituents are calcium chloride and potassium chloride.

UNSPSC 51122700 Combination cardiovascular agents (Class) covers state and local procurement of cardiovascular medications used in emergency response, hospital care, and pharmacy benefit programs. State and local buyers under this code source specific formulations—labetalol, epinephrine, adenosine, diltiazem, and generic multi-source cardiovascular drugs—through sealed bids, cooperative purchasing agreements, and direct-to-manufacturer programs. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP). Emergency medical services and hospital pharmacy systems represent the primary end users, with procurement often structured to support one-year base terms plus renewal or extension options.

Recent activity spans Florida, Texas, and multistate cooperative coverage including Oregon and Minnesota. The City of Tampa's Purchasing Department solicited sealed bids (26P00188) for Advanced Life Support Medications in April 2026, requiring 370 units of labetalol HCI 100mg vials, 1,810 units of epinephrine 1:10,000 injections, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials with a $40,000 estimated contract value and a 5 percent SLBE bid discount. The Texas HHS Commission issued an RFI (HHS0017013) in early April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative contracting models for cardiovascular and other therapeutic classes. MMCAP's RFP (S1070000015802), due March 26, 2026, sought generic multi-source pharmaceuticals and OTC products through three authorized wholesalers with a July 1, 2026 effective date and weighting 75 percent on price competitiveness. Vendors must comply with cGMP, DSCSA, FDA requirements, and maintain six-month minimum shelf life with one-year minimum expiration from manufacture.